The trial is predicated on the notion that high-risk prostate cancer includes a range of patients, from those with localised disease and poor prognostic characteristics (based on T category, PSA, and Gleason score) to those presenting with metastatic disease, and that current therapies have limited long-term efficacy in many cases. The gene discussed is KLK3; the disease is prostate cancer.